Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025

24-month follow-up data from randomized Phase I part of the Phase I/II trial of TG4050
in resected locally advanced head and neck cancer selected for rapid oral presentation
at ASCO on June 1^st, 2025